← All trials
NCT06265428
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 29, 2024
- Primary completion
- Feb 28, 2026
- Completion date
- Feb 28, 2026
- First posted
- Feb 20, 2024
- Last posted
- Feb 20, 2024
- Enrollment
- 224
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- DualityBio Inc.Lead sponsor
- BiontechCollaborator
- DualityBio Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.